Tafamidis improves outcome in transthyretin amyloid cardiomyopathy

In a Hot Line presentation yesterday, Professor Claudio Rapezzi (University of Bologna, Bologna, Italy) reported exciting data from the phase III ATTR-ACT trial in 441 patients with transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrating that tafamidis, a selective transthyretin stabiliser, is able to improve survival and quality of life in this patient population.¹

Prof. Rapezzi notes that, “ATTR-CM can be inherited as an autosomal dominant trait caused by mutation in the TTR gene (ATTRm), or by deposition of wild-type transthyretin protein (ATTRwt), previously called senile systemic amyloidosis. Awareness of the disease among cardiologists is low, and ATTR-CM is therefore underdiagnosed.” Although prevalence is uncertain, studies using a non-biopsy approach to diagnosis (total body scintigraphy with bone tracers)² demonstrate a prevalence of at least 13% in hospitalised heart failure patients with preserved ejection fraction,³ 16% in patients undergoing transcatheter aortic valve replacement for severe aortic stenosis⁴ and 5% in patients with presumed hypertrophic cardiomyopathy.⁵ According to Prof. Rapezzi, “Treatments have been limited to supportive care, with no guideline-based recommended treatment, and the median survival of untreated patients is only around 3.5 years after diagnosis.”¹

Current treatment options for ATTR-CM are extremely limited; none are able to prolong survival or improve quality of life.

Tafamidis, a novel non-NSAID benzoxazole derivative, binds to the transthyretin thyroxine binding sites with high affinity and selectivity inhibits dissociation of tetramers into monomers, the rate-limiting step in the formation of TTR amyloid. “Although tafamidis was the first pharmacotherapy approved to slow the progression of peripheral neurologic impairment in transthyretin amyloid polyneuropathy,” explains Prof. Rapezzi, “its role in ATTR-CM has not yet been explored in any randomised clinical trial and ATTR-CM remains a treatment orphan disease.”

The ATTR-ACT trial investigated the efficacy and safety of tafamidis (80 mg or 20mg once daily for 30 months; n=264) vs placebo (n=177) in patients with hereditary and wild-type ATTR-CM who had a typical echocardiogram, transthyretin amyloid in any biopsy tissue, a plasma NT-proBNP ≥600 pg/mL and a 6-minute walk test of >100 m. The primary efficacy endpoint was a hierarchical combination of all-cause mortality or cardiovascular hospitalisations.

Continued on page 2...
mortality and frequency of cardiovascular-related hospitalisations. Secondary endpoints included change from baseline to month 30 in the 6-minute walk test and the Kansas City Cardiomyopathy Questionnaire overall score.

“Tafamidis is the first treatment demonstrated to improve survival and quality of life in patients with ATTR-CM.”

“Compared with placebo, tafamidis demonstrated a significant reduction in all-cause mortality (29.5% vs 42.9%; hazard ratio [HR] 0.70; 95% confidence intervals [CI] 0.51-0.96; p=0.0259) and cardiovascular-related hospitalisations (0.48 vs 0.70; relative risk reduction 0.68; 95% CI 0.56-0.88; p=0.0001) with significant improvement in quality of life,” says Prof. Rapezzi. “The treatment could make a real difference to the lives of individuals diagnosed with hereditary or wild-type ATTR-CM.”


Hugo A. Katus: Pioneer of the cardiac-specific troponin T immunoassay

The cardiac-specific troponin T (c-TnT) immunoassay revolutionised the diagnosis and management of myocardial injury. Professor Hugo Katus (Heidelberg University Hospital, Heidelberg, Germany), President of the German Cardiac Society, and the man behind decades of work that led to the development and commercialisation of the c-TnT assay, explains why it has been so successful and what is important for the future.

Prof. Katus’ 40-year career began with a research fellowship in the laboratory of Edgar Haber at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, where he started to develop highly specific immunomasays to measure myofibrillar proteins in blood as a diagnostic tool for myocardial cellular necrosis. The initial development of a myosin light chain assay was eventually abandoned due to the insufficient cardiac specificity of these proteins, which are also expressed in slow skeletal muscle. However, in the 1980s he discovered that c-TnT could be distinguished from skeletal troponin T isoforms by monoclonal antibodies, which led to the development of a truly cardiac-specific assay.

What are the key factors that made development of the c-TnT assay possible? “Most importantly, we knew that troponin was an ideal marker,” says Prof. Katus. “What was needed was translation of our laboratory-based ideas and work into clinical practice, and for that to happen we realised that industrial support was critical.” Pharmaceutical company collaboration resulted in the joint protection of his original work by European and international patents and the necessary investment for the development of a highly sensitive c-TnT assay.

It took over ten years of further work before c-TnT was established as a cardiac marker in the clinical setting, and Prof. Katus acknowledges that the translation of a novel idea to a clinical application is not without frustrations. “Initially, there was some scepticism as to the value of the novel c-TnT assay,” he says. “People are not always willing to accept new ideas and I remember when we were trying to publish our novel results, one reviewer commenting that it is already known how to diagnose myocardial injury, and that our work would just confuse the clinical community.” Persistence in demonstrating that the c-TnT assay was better than the existing enzyme assays was important, as was ensuring independent evaluation of his team’s research through multicentre trials to confirm their laboratory findings. What finally convinced the clinical community was the finding that a positive test is more harmful than a negative one, because troponin-positive (but creatinine kinase-MB-negative) patients gained benefit from targeted and more aggressive treatment. Also significant was that in early 2000 a working group of the ESC/AHA redefined acute myocardial infarction, endorsing the diagnostic use of cardiac troponins instead of cardiac enzymes or creatinine kinase-MB mass.

“Troponin transformed the way we think about biomarkers. Its clinical significance is huge; it is at least as important in the diagnostic work-up as ECG.”

When asked why he thinks cardiac troponin is such a successful biomarker, Prof. Katus is clear, “It’s successful because of its unique characteristics. As well as it being cardiac-specific, we knew from our work on myosin light chain that the intracellular concentration of troponin was high and so the protein pool was large. Furthermore, many troponin T epitopes are well preserved in their protein structure once released into the circulation—it is a good, stable analyte.”

In its early clinical use to test for myocardial injury, the c-TnT assay led to nearly twice as many cases being detected. Soon afterwards, it was realised that any insult to the heart, e.g. myocardial infarction or toxicity after chemotherapy, resulted in elevated troponin levels and clinicians were able to detect damage due to ongoing disease and also predict poor outcome. The next diagnostic level is that high-sensitivity assays can detect even less injury, and troponin levels can now be measured in apparently healthy people, potentially indicating earlier-stage disease.

Is this the future direction for the troponin assay? Prof. Katus thinks so. “The future is even greater sensitivity and less invasive assays. Work in this area is ongoing to gain more understanding with high-sensitivity tests and the detection of very early stages of cardiovascular diseases associated with troponin levels in the blood.” So, a lifetime of experience has brought about great changes in diagnostic capabilities. Prof. Katus emphasises, “This assay is the result of decades of work; the process of development generates data that are not always acceptable by high-impact journals but which, for the troponin assay, ultimately demonstrated its reproducibility and confirmed its clinical impact in furthering progress in medicine—and that is what is most important.”


Past-President of the ESC, Professor Fausto Pinto (University of Lisbon, Lisbon, Portugal), was instrumental in the launch of the ESC Professional Membership scheme at ESC Congress 2016 as part of a 5-year strategic plan devised to ensure that the ESC continues to meet the challenges of improving cardiovascular health.

“We created the membership scheme to expand the possibility of members engaging with the ESC and its different activities,” explains Prof. Pinto. “Membership at the level of the Associations was already in place and we wanted to combine these with a more global membership for ESC as well as supporting membership of the 56 National Cardiac Societies. “It was also important to expand the reach of ESC, particularly to include all cardiovascular health care professionals from different specialities and engage new international members from across the world. Additionally, we wanted to provide improved access to the many resources that the Society offers.” ESC membership comes with an array of resources and educational tools including free online access to the ESC textbook and the European Heart Journal or Cardiovascular Research, ESC Pocket Guidelines, and e-learning activities. Another important aim of the Professional Membership scheme was to expand connections. “We wanted to stimulate networking and create more opportunities to advance knowledge and help colleagues around the world interact with the different communities, to work together on new initiatives and to become involved in more of the activities of the ESC.”

“Since its implementation in Rome in 2016, the ESC Professional Membership scheme has been very successful in engaging many members from around the world.”

www.escardio.org/ESC2018

Solution: Giant aneurysm of the non-coronary sinus of Valsalva

Brought to you by the European Association of Cardiovascular Imaging (EACVI)

Transesophageal echocardiography, short axis view at the aortic valve level (typical frame). A part aneurysm of the non-coronary sinus of Valsalva can be seen, the other two sinuses being normal sized.
Reducing stroke burden through cardiologist–neurologist collaboration

Acute ischaemic stroke is a catastrophic cardiovascular event that may be life changing/limiting. Many patients experiencing a stroke have an underlying cardiovascular comorbidity that may or may not have been previously diagnosed at the time of the stroke. Indeed, evidence suggests that around half of ischaemic strokes may be caused by heart disease.1

As such, optimal stroke prevention and treatment (including primary and secondary prevention, acute diagnostics and acute intervention) requires a multidisciplinary approach involving both1 cardiologists and neurologists. In recognition of this, the ESC Council on Stroke was created in 2016 with aims to promote interdisciplinary cooperation, education and research on stroke and ultimately reduce the burden of cardiovascular disease in Europe.2 In the council’s first educational workshop in Prague earlier this year, cardiologists, neurologists, radiologists, surgeons and other specialists gained the opportunity to form close interdisciplinary contacts while learning about stroke pathophysiology, the role of multidisciplinary stroke teams and the latest research on stroke prevention and management. “This was a unique opportunity for an intense interdisciplinary dialogue to learn and discuss latest evidence, clinical concepts and new insights in stroke from multiple specialist perspectives. The need and the growing interest in such close collaboration was underscored by the wide range of topics and the excellent and vivid discussion in all sessions of our meeting,” says Professor Wolfram Doehner (Center for Stroke Research, Charité, Universitätsmedizin Berlin, Germany), Vice-Chairperson of the ESC Council on Stroke. He continues, “There are heart-brain interactions in almost any cardiovascular pathology that need to be addressed with special emphasis, such as in the field of heart failure.3 Interdisciplinary meetings are essential to advance highly specialised treatment concepts towards modern and truly comprehensive health care strategies. The overwhelming success of the workshop has led the Council on Stroke to promote a further enhanced and interactive, international conference ‘ESC Heart & Stroke’ being planned for January 2019 in Berlin, Germany.4

If you want the latest insights on stroke and to discuss them with cardiologist and neurologist experts, attend the Council on Stroke meeting ‘ESC Heart & Stroke 2019’, on 25 – 26 January in Berlin, Germany.

At ESC Congress 2018, several cardio-stroke sessions and activities are taking place with active contribution of the ESC Council on Stroke. Today, the Council and the European Stroke Organisation (ESO) will present a joint session ‘Stroke and the heart’, co-chaired by Professor Martin Koehrmann (deputy director of the Clinic of Neurology University of Essen, Essen, Germany), board member of ESO, and Professor Alison Halliday (a vascular surgeon from the University of Oxford, Oxford, UK), board member for the ESC Council on Stroke. This important and enlightening session will include presentations on ‘The relationship between stroke and atrial fibrillation’, ‘Anticoagulation after stroke - when to restart and how?’ Patients with high cerebral bleeding risks: Who, when and how should we treat with anticoagulants?’ and ‘Thrombectomy with or without thrombolysis - what is the optimum strategy for stroke?’

Don’t miss the joint ESC and ESO session ‘Stroke and the heart’ today, 11:00 - 12:30, Damascus, Spotlight Village.

A current hot topic in stroke management is mechanical thrombectomy. While intravenous thrombolysis remains the standard medical therapy for most acute ischaemic stroke patients, recent evidence has consolidated a role for mechanical thrombectomy in selected patients, including those for whom thrombolysis is contraindicated.5,6 However, there is an acute shortage of interventional neurologists in Europe to provide this procedure within the optimum timeframe. Encouragingly, recent data from the prospective registry PRAGLUE-16 have indicated that acute stroke interventions performed in close collaboration between cardiologists, neurologists and radiologists are both feasible and safe.7 “We have evidence showing that interventional cardiologists who have received a short period of training on the mechanical thrombectomy procedure to treat acute ischaemic stroke can achieve the same results as interventional neurologists,” says Professor Petr Widimsky (Charles University, Prague, Czech Republic), Chair of the ESC Council on Stroke. “Given that most interventional cardiology units already contain the medical equipment for mechanical thrombectomy and that many interventional cardiologists routinely perform carotid artery stenting, to train them to perform intracranial mechanical thrombectomy can be much faster (i.e. less than three months) compared with the longer training needed in case of no previous interventional catheter experience,” continues Prof. Widimsky. The ESC Council on Stroke is currently putting forward a proposal asking national health authorities to give permission to provide this shortened training to interventional cardiologists.1

“Forming a close collaborative network among interventional cardiologists and neurologists will make a huge difference to managing patients with acute ischaemic stroke,” says Prof. Widimsky.

GLOBAL LEADERS trial: Long-term ticagrelor monotherapy after stenting does not improve outcomes vs standard dual antiplatelet therapy

In a Hot Line session yesterday, Professor Patrick Serruys (Erasmus University, Rotterdam, The Netherlands) presented the latest findings from a breaking data from a large superiority study of a new long-term antithrombotic strategy after coronary stenting, which were simultaneously published in The Lancet.1,2

The investigator-initiated, randomised, open-label GLOBAL LEADERS trial included almost 16,000 patients scheduled to undergo percutaneous coronary intervention for stable coronary artery disease (SCAD) or acute coronary syndromes (ACS). Patients, implanted with biolimus-eluting stents and given the thrombin inhibitor bivalirudin, were randomised to receive aspirin and the P2Y12 inhibitor ticagrelor for 1 month, followed by ticagrelor monotherapy for 23 months (n=7968) – the experimental group – or 12 months of standard treatment with dual antiplatelet therapy (clopidogrel in patients with SCAD or ticagrelor in those with ACS), followed by aspirin monotherapy for a further 12 months (n=7968). The composite primary endpoint was the cumulative incidence of all-cause death or new Q-wave myocardial infarction (MI) within 2 years and the secondary endpoint was the rate of moderate or severe bleeding (class 3 or 5 on the Bleeding Academic Research Consortium scale) over the 2-year period.

At 12 months, all-cause mortality or new Q-wave MI was significantly lower in the experimental group than in the standard dual antiplatelet therapy group (1.95% vs 2.47%, respectively, risk ratio 0.79; p=0.028). The rate of moderate/severe bleeding was numerically, though not statistically significantly, lower in the experimental group (4.37% vs 4.70% in the reference group, risk ratio 0.86 [95% CI]).

At 24 months, the difference in all-cause mortality or new Q-wave MI in favour of the experimental group persisted (3.81% vs 4.37% but was no longer statistically significant (risk ratio 0.87; p=0.073), and moderate/severe bleeding was similar in each group (risk ratio 0.97).

“A landmark analysis starting at one year suggested no additional benefit of monotherapy with ticagrelor in the second year.”

“If the trial had been completed and terminated at one year, it may have demonstrated superiority of the experimental arm,” explains Prof. Serruys. “The lack of treatment adherence in the ticagrelor arm, mainly during the second year, may have compromised the demonstration of superiority. A careful per-protocol/per-treatment analysis will try to elucidate this point,” he adds.

The trial was not designed to assess non-inferiority, further studies are needed to confirm that monotherapy is no less effective than extended dual antiplatelet therapy. “The risk of monotherapy compared to extended dual therapy was 0.76–1.01, suggesting that monotherapy is relatively safe,” says Prof. Serruys.

ESC Gold Medal Award winner
From bench to bedside: Linking research with clinical cardiology

Prof. Evgeny Shlyakhto
Director General of the Almazov National Medical Research Centre, St. Petersburg, Russia
President of the Russian Society of Cardiology, knew he wanted a career in medicine from a young age.

“The death of my grandfather, a military doctor, during WWII in 1942 was talked about a lot when I was growing up and this instilled in me the desire to be a physician—I could not have imagined myself in any other profession,” he recalls. With this ambition, he graduated with a degree in medicine in 1977 from the Pavlov Medical University in St. Petersburg, where, as a student, he was lucky enough to join the clinical team led by the prominent Russian cardiologist, Vladimir Almazov. “It was the tradition that students worked very much as part of the clinical team; this made a great impression on me and encouraged my decision to become a cardiologist,” remembers Prof. Shlyakhto.

“Early in his career, Prof. Shlyakhto’s research interests focused on autonomous regulation of the blood circulation. "Arterial hypertension was also a particular area of interest because it was very relevant and, at the time, there were newer treatments being developed rapidly," he says. Epidemiology of hypertension, obesity and metabolic syndrome, and molecular and cellular mechanisms of heart failure development are other areas in which he has directed his interest. With the rapid development of cardiac surgery, he switched his focus to cytoreductive approaches in open-heart surgery using pre- and post-conditioning for prevention of myocardial ischemia-reperfusion injury, and later ischemic and pharmacological post-conditioning during percutaneous coronary interventions. More recently, with the emerging era of precision medicine, Prof. Shlyakhto has turned his attention to cytogentic and the cultivation of stem cells, endothelial precursor cells and foetal cells as well as development of cell therapy methods for the treatment of cardiovascular diseases. "Genomic editing is, in my opinion, very important in the treatment of heart failure and other cardiovascular diseases; I think this will lead to a dramatic breakthrough in cardiology and it’s an area in which Russian cardiologists have a lot of experience," he says. In addition to citing Vladimir Almazov as a positive influence early on in his career, Prof. Shlyakhto credits some of the founding fathers of Russian medicine as a source of inspiration. “Working in St. Petersburg, I am constantly inspired by our great history,” he says, “by physicians such as the Nobel Prize winner Ivan Pavlov, Nikolai Korotkov—inventor of the auscultative method of blood pressure measurement, one of the most famous discoveries in the field of hypertension—and Vasilii Kolesov, who carried out the first coronary bypass surgical operation in 1964.” As for lessons he has learned during his career, Prof. Shlyakhto thinks that the importance of continuing medical education is among the most significant. “Cardiologists of tomorrow need a lot of knowledge. They must not stop learning and, as such, it is vital to have communication between specialists in medicine, physiology, chemistry and biology—multi-disciplinary approach is so important,” he advises. Indeed, such an approach has been integral to the success of the scientific school he founded, which is known for its continuity of tradition and interdisciplinary approach.

Throughout his career, Prof. Shlyakhto has been a big proponent of translational therapy. “I am pleased that I have been able to provide a bridge between molecular biology and clinical cardiology,” he says. This is evident in his leadership of the Almazov National Medical Research Centre, which is an impressive example of a translational approach to cardiovascular medicine. He is also heavily involved in social, scientific and organizational work aimed at integrating Russian medical science into the global scientific community. Indeed, one of his proudest achievements is the way in which the Russian Society of Cardiology participates in ESC activities. “I am very proud that the Russian Society is a part of the European family—the way we are working together to address the same problems, the same challenges.” And what advice would he give to young cardiologists today? Prof. Shlyakhto doesn’t hesitate. “Never stop learning, do not limit yourself, be compassionate and, most importantly, think of your patients.”

Professor Evgeny Shlyakhto

The development of stents has revolutionised coronary angioplasty, improving and saving the lives of millions of patients. These days, many stent designs exist—both bare metal and drug-eluting stents—all of which are derivatives of the original Palmaz-Schatz stent.

With constantly evolving and improving designs, stents have become accepted worldwide as the cornerstone of interventional therapy for coronary artery disease. However, the history of stent development began back in the late 1970s. According to Doctor Richard Schatz (Scirps Clinic, La Jolla, California, USA), co-inventor of the Palmaz-Schatz stent, the first coronary stent to be approved by the FDA, in 1994, “I began collaborating with Doctor Julio Palmaz, formerly at the University of Texas, USA, on stent development in 1985. I was at the Brooke Army Medical Center (San Antonio, Texas, USA) at the time. Dr. Palmaz had conceived the idea of a balloon-expandable ‘scaffold’ to hold the artery open after seeing ground-breaking research on balloon angioplasty presented by Doctor Andreas Gruntzig in 1977.” While dramatically successful at opening blocked arteries, balloon angioplasty was often limited by abrupt artery closure and restenosis. “Early exploratory stent devices included self-expanding springs; however, these were hampered by delivery issues and high complication rates. Dr. Palmaz designed a balloon-expandable stainless-steel slotted metal tube, instead of a spring or coil. By trying different designs and types of metal, we ultimately developed the Palmaz-Schatz stent. We placed our first stents in dog coronaries in 1985 and, with funding support from Johnson & Johnson, in the first humans in 1987,” continues Dr. Schatz.

“The impact stents have had on relieving mortality and morbidity, improving patients’ lives and on reducing health care costs has been immeasurable and thirty years later nothing has replaced them as the frontline treatment for atherosclerosis,” says Dr. Schatz.

Followings its success—the Palmaz-Schatz stent has been identified as one of the top 10 medical device patents of the last 50 years, and the basic balloon-expandable slotted tube metal platform design has stood the test of time—Dr. Schatz has continued his seminal work and currently holds the patent to a variety of coronary stents. “Newer stent designs have drug coatings with anti-proliferative agents to reduce the rates of in-stent restenosis. The challenge now is to develop the right mix of drugs and coatings to eliminate the risk of thrombosis and restenosis entirely.”

Myocardial Revascularization

The 2018 ESC/EACTS Guidelines on Myocardial Revascularization1 feature some very interesting updates on knowledge that will impact clinical practice, thinks Dr. David Glineur (University Hospital Southampton, Southampton, Cambridge, UK) and Dr. Iain A. Simpson (Cambridge School of Clinical Medicine, University of Cambridge, UK). “Previously, a doctor’s decision about whether to use a coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) was made almost exclusively on an individual patient basis. However, sufficient data have now accumulated to confirm that patients with diabetes form a distinct group and that coronary surgery is the best approach to ensure a good long-term outcome for these individuals, even in those with a low SYNTAX score.”

“The finding that revascularisation technique can be guided by diabetic status is completely new and provides clinicians with a rapid way of selecting the optimum method for certain patient groups.”

One of the most notable changes in this latest update of the guidelines is that renal function has been moved from an individual patient basis to becoming a key feature in the new guidelines. “Previously, a doctor’s decision about whether to use a coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) was made almost exclusively on an individual patient basis. However, sufficient data have now accumulated to confirm that patients with diabetes form a distinct group and that coronary surgery is the best approach to ensure a good long-term outcome for these individuals, even in those with a low SYNTAX score.”

“The finding that revascularisation technique can be guided by diabetic status is completely new and provides clinicians with a rapid way of selecting the optimum method for certain patient groups.”

The use of multiple-artery CABG is another of Dr. Glineur’s highlights. “The bulk of the latest scientific evidence favours the use of radial artery and left internal mammary artery, over single-artery approaches, and the endorsement of this approach is approaching a grade IB recommendation,” he explains. Dr. Glineur is also happy to report that the role of a multidisciplinary heart team in management is high on the list of recommendations. “This was first proposed in 2014,” he says, “but features much more prominently in the latest guidelines. I think it is really important that we continue to recognise this as being fundamental to optimising patient care. As an example, in elective revascularisation procedures, the use of ad hoc PCI is increasingly being regarded as unjustifiable in the setting of stable coronary disease with intermediate or high SYNTAX score, and treatment decisions, based on the best evidence set out in treatment guidelines, should consider input from all team members.” What are the other major or significant changes? “In terms of preprocedural examinations, the 2018 guidelines give more weight to the use of instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) as new tools to help in the assessment of coronary artery stenosis severity,” says Dr. Glineur. “Although the visual inspection of coronary stenosis remains a standard approach.”

Regarding devices, he comments, “We have seen a real decline in evidence to support the implantation of resorbable drug-eluting stents. A move to reduce their use was proposed in the previous guidelines and this advice is strengthened in the latest version, to the extent that, wherever possible, the use of these types of stent should be avoided.”

Dr. Glineur is proud of the latest myocardial revascularisation guidelines and wants to express his thanks to the large team of committed individuals involved in putting them together. “This is a gruelling task! Until I became involved in the guidelines, I had no idea about the time and intellectual demands required to produce them;” he confesses. However, the result is a series of guidelines that are based on the very latest scientific evidence and that are subject to rigorous expert review. “The ESC/EACTS Guidelines are probably the most frequently updated of all guidelines and apart from other guidelines and making the guidelines of choice in clinical practice settings around the world.”


CARDIOVASCULAR DISEASES DURING PREGNANCY

“Many cardiologists have limited experience of treating pregnant patients; these guidelines are helpful both in terms of management and referral to specialist care.” — Dr. Simpson.

“I think the authors have done a great job of updating the guidelines and incorporating new evidence on diagnostic techniques, risk assessment and pharmacotherapy.” — Prof. Deaton.

It is hoped that these updates will significantly impact clinical practice to ensure that mothers and babies are getting the right treatment, at the right time, by the right people. As Dr Simpson emphasises, “It’s very important that we do what we can to give the most appropriate treatment for the best outcome for both mother and baby. It must not be forgotten, however, that our main priority is to manage the mother and make sure that she is safe during her pregnancy and beyond.”

Sessions of the day

7:30
- Caloric restriction prolongs life time - Should we skip a meal today?
- Antithrombotics and cancer: challenges in clinical practice

10:15
- Setting the COMPASS into new directions - Reducing risk in chronic kidney disease and peripheral artery disease - Experts on the Spot organized by Bayer AG

12:45
- Digital Health: Technology showcase

13:00
- Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for clinical practice - Experts on the Spot organized by PACE-CME - Physicians’ Academy for Cardiovascular Education

14:00
- ESC TV Stage - Meet the trialist - PURE

14:30
- Digital Health Stage - Big Data

ESC Congress News - Tuesday 28 August

10:00
- Copenhagen - ESC General Assembly

10:05
- Meet the Task Force of the 2018 ESC Guidelines on Syncope

10:10
- Setting the COMPASS into new directions - Reducing risk in chronic kidney disease and peripheral artery disease - Experts on the Spot organized by Bayer AG

10:15
- Antithrombotics and cancer: will recent evidence change clinical practice? - Experts on the Spot organized by Deutsches Herzzentrum Berlin GmbH

12:35
- Digital Health Stage - Meet the Expert - Mobile health in adults with congenital heart disease

13:00
- Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for clinical practice - Experts on the Spot organized by PACE-CME - Physicians’ Academy for Cardiovascular Education

13:10
- Cardiovascular drug therapy in special populations

13:30
- Cardiovascular drug therapy in special populations

14:00
- ESC TV Stage - Meet the trialist - PURE

14:30
- Digital Health Stage - Big Data

Further information is available on the ESC Congress App

www.escardio.org/ESC2018
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Vienna</td>
<td>CT in patients with suspected acute coronary syndrome</td>
</tr>
<tr>
<td>15:05</td>
<td>Brussels</td>
<td>Immune mechanisms in atherosclerosis</td>
</tr>
<tr>
<td>15:10</td>
<td>Moscow</td>
<td>The future of heart failure therapy - When failure is not an option</td>
</tr>
<tr>
<td>15:15</td>
<td>Kiev</td>
<td>Primary prevention of sudden cardiac death with the ICD: still &quot;life&quot; after SABIS?</td>
</tr>
<tr>
<td>15:20</td>
<td>Tunis - Library Room</td>
<td>Difficult anticoagulation management in atrial fibrillation: a case-based approach</td>
</tr>
<tr>
<td>15:25</td>
<td>Madrid</td>
<td>Is atrial fibrillation ablation a mature treatment to reduce morbidity/mortality?</td>
</tr>
<tr>
<td>15:30</td>
<td>Bach</td>
<td>Tips for getting out of trouble in the EP and device labs</td>
</tr>
<tr>
<td>15:35</td>
<td>Agora 1</td>
<td>The role of platelet function in acute coronary syndromes</td>
</tr>
<tr>
<td>15:40</td>
<td>Agora 2</td>
<td>Antiplatelets - New insights</td>
</tr>
<tr>
<td>15:45</td>
<td>Science Box 1</td>
<td>Drug therapy in congenital heart disease - What are the options and the needs?</td>
</tr>
<tr>
<td>15:50</td>
<td>Science Box 2</td>
<td>Novel atherothrombogenic mechanisms</td>
</tr>
<tr>
<td>15:55</td>
<td>San Marino</td>
<td>Arteriogenic cardiomyopathy: From pathology to prognosis</td>
</tr>
<tr>
<td>16:00</td>
<td>Copenhagen</td>
<td>Hypertension and hypertension: look harder!</td>
</tr>
<tr>
<td>16:05</td>
<td>Ljubljana</td>
<td>Exosomes: new players in cardiovascular disease</td>
</tr>
<tr>
<td>16:10</td>
<td>Bach</td>
<td>Advanced heart failure</td>
</tr>
<tr>
<td>16:15</td>
<td>15:45</td>
<td>Digital Health Stage - Computer Decision Support</td>
</tr>
</tbody>
</table>

ESC Congress 365 is now ESC 365. This all-new platform includes resources from ESC Congress and ESC subspecialty congresses. It features an enhanced, easy-to-use search function so all these materials are at your fingertips on one platform. You can access presented slides, videos, e-posters and abstracts as well as insightful perspectives from key opinion leaders. With ESC 365, you can watch the sessions you missed or replay presentations of particular interest—all at your convenience.

ESC 365 is freely available to ESC Professional Members, Association Members (Ivory, Silver, Gold) and all Fellows of the ESC throughout the year. Special offers also exist for young cardiologists.

ESC 365: More than 84,500 slide sets, videos and abstracts from the ESC family of congresses on one new platform. Visit www.escardio.org/365 today!

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance and Novartis Pharma AG in the form of an educational grant.
In the lead worldwide in 2018

The ESC Journal Family: In the lead worldwide in 2018

The ESC Journal Family

“Phase III MITRA.fr study: Percutaneous mitral valve repair improves mitral regurgitation but not outcome

First data from the recently completed MITRA.fr trial were presented yesterday by Professor Jean-François Obadia (Hôpital Louis Pradel, Lyon, France) in a Hot Line session. “For the first time, we have high-level evidence relating to the safety and efficacy of a Mitraclip device in patients with severe secondary mitral regurgitation (SMR) and chronic heart failure,” he notes.

Prof. Obadia explains that, “SMR is a major prognostic factor in patients with chronic heart failure. While the condition can be corrected, we don’t currently know whether this offers significant clinical benefit and this is what the trial set out to investigate.”

Over a 3-year period, patients were recruited to the study from 37 French centres; after centralised echographic Core Lab assessment, 307 patients were randomised in a 1:1 ratio to percutaneous mitral valve repair (pMVR) with the MitraClip system in addition to optimal medical treatment (OMT; intervention group; n=152), or to OMT alone (control group; n=152). The primary efficacy endpoint was a composite of all-cause death and unscheduled hospitalisation for heart failure at 12 months. At baseline, patients (mean age 70 years; 74% males) were severely symptomatic with New York Heart Association (NYHA) class 4. The mean left ventricular ejection fraction was 33% and the functional mitral regurgitation (MR) was severe, with a mean regurgitant orifice area of 31 mm². Patients were considered by a heart team to be ineligible for surgery.

“The safety of the MitraClip system was high,” says Prof. Obadia, “with no conversion to surgery and no procedural mortality. In addition, the rates of vascular complication (3.4%), tamponade (3.3%) and cardiac embo liths (stroke) (3.3%) were all acceptable.” The efficacy results obtained are promising, he says. “The technical success of the procedure, according to Mitral Valve Academic Research Consortium criteria, was 96%. After 12 months, the MR was significantly reduced in the MitraClip group, with 83% of MR ≤ grade 2 versus 0 at baseline.” However, despite the apparent safety and efficacy of the MitraClip, the results did not translate into improved outcomes when compared to a control group, reports Prof. Obadia.

“There was absolutely no benefit of the MitraClip in terms of survival rate or risk of rehospitalisation for heart failure at 12 months and the primary endpoint was negative.” Prof. Obadia continues, “Based on the confirmation of our statistical hypotheses and a follow-up of at least 99%, we can be confident that this conclusion is very robust. Moreover, the negative results seen in the primary analysis were observed also in the per-protocol analysis and all sub-group analyses.” He goes on to say that, “The medical treatment in the two groups was very good and in accordance with recommendations. A similarly improved clinical status was seen in both groups.”

“To sum up,” says Prof. Obadia, “we can say that MitraClip was safe and effective at reducing the MR but that the primary composite endpoint, including all-cause death and unplanned hospitalisations for heart failure at one year was not significantly different between groups.” He finishes with a plea, “If our conclusion on the primary endpoint seems robust, our analysis on a smaller sub-group of patients is more fragile. Therefore, more randomised studies are necessary to confirm our results and to define possible sub-groups of patients who could really benefit from mitral valve repair.”


The new journal in the family, EHJ – Case Reports, really stands out for its primary aim of promoting the education of junior cardiologists, both through its published content and the chance it gives doctors to get experience with the manuscript review and editorial process. “This is a really good opportunity for young cardiologists at the start of their career,” says Prof. Lüscher. “Senior House Officers, for example, are very busy and have interesting cases that are ideal for writing up as a case report. This is a great way of learning how to write a paper and it opens the door to clinical research.”

In 2017, EHJ became the highest ranking cardiology journal in the world, a position it retained in 2018. Prof. Lüscher thinks that ESC’s drive to widen the journal’s audience to the global cardiology community has paid off. “That EHJ continues to lead the top three journals, ahead of Circulation and Journal of the American College of Cardiology, is a great achievement and reflects the move to invite contributions from distinguished cardiology professionals around the world,” he says. “When one considers that a half of all the papers published today come from authors in the USA, EHJ and its sister journals have to pursue a global approach to reflect science at large.” He regards EHJ’s achievement as a success not just for the individual journal but for the whole ESC journal family, three of which now feature in the top ten Cardiovascular Systems Impact Factor category journals (Table).”

“The new journal in the family, EHJ – Case Reports, really stands out for its primary aim of promoting the education of junior cardiologists, both through its published content and the chance it gives doctors to get experience with the manuscript review and editorial process. “This is a really good opportunity for young cardiologists at the start of their career,” says Prof. Lüscher. “Senior House Officers, for example, are very busy and have interesting cases that are ideal for writing up as a case report. This is a great way of learning how to write a paper and it opens the door to clinical research.”

In 2017, EHJ became the highest ranking cardiology journal in the world, a position it retained in 2018. Prof. Lüscher thinks that ESC’s drive to widen the journal’s audience to the global cardiology community has paid off. “That EHJ continues to lead the top three journals, ahead of Circulation and Journal of the American College of Cardiology, is a great achievement and reflects the move to invite contributions from distinguished cardiology professionals around the world,” he says. “When one considers that a half of all the papers published today come from authors in the USA, EHJ and its sister journals have to pursue a global approach to reflect science at large.” He regards EHJ’s achievement as a success not just for the individual journal but for the whole ESC journal family, three of which now feature in the top ten Cardiovascular Systems Impact Factor category journals (Table).”

MUCH MORE TO FOLLOW

“Of the advantages of having a journal family is that the newer titles benefit from having a flagship journal to really help them get off the ground.”

Much as ESC members help and support each other, so do the journals in the ESC family, says Prof. Lüscher. “One of the most important ways we do this is by sharing manuscripts and targeting them to the most relevant audience. For example, EHJ receives many manuscripts that are of excellent quality but that are not really suitable for the general cardiology audience of the journal. Regular liaison between the editorial boards of the different journals means these types of manuscripts, rather than being rejected, can be recommended for publication in one of EHJ’s more specialist sister journals, with the permission of the author,” he explains. “We are currently transferring 350–400 articles per year to other journals in the family. This is beneficial not only for the authors but also for the journals, particularly the newer ones, which can find it difficult to become established, particularly when they have not received an Impact Factor.”

The strong links between the journals mean that the ESC Journal family grows from strength to strength and with 15 titles covering the spectrum of cardiovascular medicine and the support of a strong flagship journal, the family’s future is looking good.

Impact Factors of the top 10 journals

<table>
<thead>
<tr>
<th>Journal Title</th>
<th>2017 Journal Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Heart Journal</td>
<td>23.425</td>
</tr>
<tr>
<td>Circulation</td>
<td>18.880</td>
</tr>
<tr>
<td>Journal of the American College of Cardiology</td>
<td>16.834</td>
</tr>
<tr>
<td>Circulation Research</td>
<td>15.211</td>
</tr>
<tr>
<td>Nature Reviews Cardiology</td>
<td>15.162</td>
</tr>
<tr>
<td>European Journal of Heart Failure</td>
<td>10.683</td>
</tr>
<tr>
<td>JACC – Cardiovascular Imaging</td>
<td>10.247</td>
</tr>
<tr>
<td>JAMA Cardiology</td>
<td>10.133</td>
</tr>
<tr>
<td>JACC – Cardiovascular Interventions</td>
<td>9.881</td>
</tr>
<tr>
<td>EHJ – Cardiovascular Imaging</td>
<td>8.336</td>
</tr>
</tbody>
</table>
No changes in survival after acute myocardial infarction in the last decade

New data from SWEDEHEART

Despite continued efforts to improve care after acute myocardial infarction (MI), the impact of the new strategies on real-life health care has not been recently documented.

Professor Tomas Jernberg (Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden) shared new data yesterday in a late-breaking presentation from the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry. “SWEDEHEART is a unique complete national registry that enables us to assess characteristics, treatment strategies and outcomes for all patients with acute MI in Sweden,” says Prof. Jernberg. Data from 371,431 patients were analysed between 1995 and 2018.

Prof. Jernberg explains, "From 1995 to 2009, with the gradual implementation of new effective treatments, such as percutaneous coronary intervention (PCI), dual antiplatelet therapy, statins and angiotensin-converting enzyme inhibitors, we saw a substantial reduction in one-year mortality in acute MI from 25% to around 15%. However, during the last 6-8 years, mortality rates have reached a plateau and remain almost unchanged. Interestingly, mortality appears to have plateaued earlier in patients with ST-elevation MI (STEMI) than in those with non-STEMI (NSTEMI).” He goes on to say, “Between 1995 and 2009, there were marked changes in management approaches, with more STEMI patients having primary PCI and more NSTEMI patients having coronary angiography but as the proportion undergoing these procedures has levelled off, so have the mortality rates.”

“Over the last 6-8 years, mortality after acute MI has reached a plateau. Simultaneously, established treatment concepts have been further fine tuned and improved but few new treatment concepts have been introduced.”

Prof. Jernberg concludes, “There is an urgent need for better individual tailoring of more costly treatments in order to maintain cost-effectiveness and we should also look at identifying new breakthrough treatments to further improve outcomes in acute MI.”

Bayer at

ESC Congress 2018

Tuesday 28th August

Satellite Symposium

13.00 – 14.00
Baku – Village 5

New Directions in the Management of Thrombotic Risks in Patients with Heart Failure?

Co-Chairs:
Faiez Zannad and John Cleland

Don't Miss Our Satellite Symposium - Experts on the Spot Sessions

16.15 – 10.45, The HUB - Bach
Setting the COMPASS into New Directions: Reducing Risk in Coronary Artery Disease and Peripheral Artery Disease

16.30 – 10.30, The HUB - Bach
New Directions in Antithrombotic Management of High Risk Patients

To learn more about our programme at ESC Congress 2018, visit us at booth #B200

© Bayer AG 2018 PP-ESR-ALL-0330-1
Prevention as an effective treatment: The ESC Prevention of CVD Programme

Prof. Diederick Grobbee

Up to 45% of deaths following a myocardial infarction could be avoided with effective secondary prevention measures, which can also significantly reduce the risk of a subsequent clinical event.

The aim of the ESC Prevention of Cardiovascular Disease (CVD) Programme—led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association and the ESC Council on Cardiovascular Nursing and Allied Professions—is to spread the word about secondary prevention and facilitate its realisation.

Professor Diederick Grobbee (University Medical Centre Utrecht, Utrecht, The Netherlands), EAPC President, explains, “This innovative programme provides a variety of educational and scientific resources designed to help doctors achieve effective prevention. Tools prepared by a multidisciplinary team are available to help with risk assessment (such as the easy-to-use online SMART risk score), treatment goals and rehabilitation, including tips on encouraging appropriate exercise, optimal selection and promotion of compliance with pharmacological treatment, managing diet and controlling risk factors, for example diabetes.”

The resources are available in a range of formats. “Health care professionals can access scientific documents, webcasts from congresses and masterclasses, and webinars,” he says. “Now in its third and final phase, the programme is looking to increase awareness within the health care community and to extend it beyond, to patients and, eventually, the general public. As a part of this, we will soon be launching a patient website to actively encourage them in the secondary prevention process,” says Prof. Grobbee. “We will also be auditing the performance of secondary prevention across Europe to monitor the implementation and, where possible, the impact of this programme.”

Check out the website for more details: www.escardio.org/Education/ESC-Prevention-of-CVD-Programme

Don’t miss!
Cardiovascular prevention in diabetes.
Today, 16:45 – 17:45; Stockholm – Village 1

Endurance training is associated with a high degree of left atrial fibrosis

The risk of atrial fibrillation (AF) typically increases with age, owing to the development of cardiovascular disease and structural damage to the heart, specifically to the left atrium.

Interestingly, an unusually high incidence of AF has been noted in healthy endurance athletes. While myocardial fibrosis is known to be present in this population, there are currently no standard techniques used to specifically quantify left atrial (LA) fibrosis. Evaluating LA fibrosis could potentially help predict an endurance athlete’s risk of developing atrial arrhythmia.

Using late gadolinium-enhancement (LGE) MRI, a team from the University of Utah, Salt Lake City, Utah, USA, quantified the degree of LA fibrosis in 16 endurance athletes compared with 20 healthy controls, and the results were presented yesterday by Doctor David Peritz. All participants underwent cardiac MRI with 3D visualisation using processing software.

Although the endurance athletes tended to have a lower body mass index and were younger than the controls (all athletes were older than 35 years of age), they had a greater mean LA fibrosis score compared with the controls: 13.7% ± 5.4 vs 11.8% ± 7.3, respectively. Dr. Peritz says that, “In our study, endurance athletes who had consistently participated in at least 10 years of competitive sports and actively trained for at least 10 hours per week had a significantly greater degree of LA fibrosis than the controls.” He adds, “What is more, being an endurance athlete appears to have a greater impact on the degree of fibrosis than any of the usual comorbidities linked to LA fibrosis, such as diabetes, hypertension and tobacco use.”

While there is a significant correlation between endurance training and the degree of LA fibrosis, as detected on cardiac MRI, the researchers caution that the clinical significance of this finding is unclear. They suggest that the increased LA fibrosis in endurance athletes could explain the higher incidence of atrial arrhythmia, including AF, in this population.
Low-dose rivaroxaban in heart failure: COMMANDER HF

In a Hot Line session yesterday, Professor Faiez Zannad (Centre Hospitalier Universitaire de Nancy, Nancy, France) presented results from the COMMANDER HF trial investigating whether low-dose rivaroxaban reduces the morbidity and mortality associated with vascular and haemostatic dysfunction in patients with heart failure (HF).1

The trial compared rivaroxaban with placebo in more than 5,000 patients with significant coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF ≤ 40%) following an episode of decompensated chronic HF. Prof. Zannad points out that, “Rivaroxaban is approved at higher doses to treat conditions such as atrial fibrillation (AF) and venous thromboembolism, but in COMMANDER HF, patients were randomised to a lower dose (2.5 mg twice daily) or matching placebo, in combination with antiplatelet therapy (2.5 mg twice daily) or matching placebo, patients were randomised to a lower dose to treat conditions such as atrial fibrillation and stroke, and the primary safety endpoint was a composite of fatal bleeding or bleeding into a critical space with potential for permanent disability. Regarding patient baseline characteristics, the median age was 66 years, the majority of patients were men (77%) and median LVEF was 34%.

Prof. Zannad explains the main findings, “During a median follow-up of 21.1 months, we found no significant difference in the primary efficacy outcome, which occurred in 25.0% of patients in the rivaroxaban group compared with 26.2% on placebo (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.84-1.05, p=0.27). There were no differences between groups in all-cause mortality or nonfatal MI but there was a significantly lower rate of nonfatal stroke with rivaroxaban vs placebo (HR 0.66, 95% CI 0.47-0.95, p=0.025).”

“We found no significant difference in the primary efficacy outcome.”

No significant difference in the principal safety outcome was observed, which occurred in 0.7% of patients in the rivaroxaban group and 0.9% in the placebo group (HR 0.80, 95% CI 0.43-1.49, p=0.48); however, patients taking rivaroxaban had a significantly higher risk of International Society on Thrombosis and Haemostasis-defined major bleeding compared with those on placebo (HR 1.68, 95% CI 1.18-2.39, p=0.003). Prof. Zannad concludes, “The most likely reason rivaroxaban failed to improve the primary efficacy outcome is that thrombin-mediated events are not the major driver of cardiovascular events in patients with recent HF hospitalisation.”

Discover more on:
www.escardio.org/JournalFamily
@ESC_Journals

ANGINA: DO NOT IGNORE THE HEART’S MESSAGES

Hey! Can’t play football with your grandson? Is angina limiting you again?

Why don’t you tell your doctor about it?

Ignoring me is not a solution, you know!

Let’s get angina under control

Supported by Servier in the form of an educational grant